Onkológia S3/2018

Management of the patient with high-risk multiple myeloma – case report

Purpose: The aim of the treatment is to control disease and to strive for deep responses and to prolong survival and maximisequality of life (QoL). Newagents such as the IMiD pomalidomide, theproteasome inhibitors carfilzomib and ixazomib, as well as themonoclonal antibodies daratumumab and elotuzumab, which may be available for patients with advanced MM, have been added. Case: We describe the management of the patient with high-risk multiple myeloma, in which we have achieved a stable disease for 8 years using a combination of different regimens. Conclusion: Despite good results in described patient the need of new combinations in the treatment of multiple myeloma with high risk still exists.

Keywords: multiple myeloma, high risk, IMiDs, proteasome inhibitors, monoclonal antibodies